2024-11-14 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**1. Performance Relative to S&P 500 (VOO):**

Johnson & Johnson (JNJ), a multinational pharmaceutical, medical device, and consumer packaged goods company, has underperformed the S&P 500 (VOO) significantly. While the S&P 500 has generated a cumulative return of 179.47%, JNJ has only returned 58.11%, leading to a **cumulative return difference of -121.36**. This places JNJ at the **29th percentile** of its historical performance relative to the S&P 500, indicating a **substantial underperformance**.

**Alpha and Beta Analysis:**

The provided data indicates a consistent, albeit decreasing, alpha for JNJ over the last 8 years. This suggests that the stock has outperformed the market (S&P 500) on a risk-adjusted basis, although this outperformance has been declining. The beta, which measures the stock's volatility relative to the market, has also consistently decreased over the past eight years, implying that JNJ has become less volatile compared to the market.

**2. Recent Price Action:**

JNJ's recent price action indicates a downtrend:

* **Closing Price:** 153.24 (Last-market: 153.28)
* **5-day Moving Average:** 154.62
* **20-day Moving Average:** 159.81
* **60-day Moving Average:** 162.17

The current price is below all three moving averages, suggesting potential further downward pressure.

**3. Technical Indicators:**

* **RSI:** 14.93 – This indicates that the stock is currently in oversold territory, which could suggest a potential bounce back.
* **PPO:** -0.52 – A negative PPO suggests that the price momentum is bearish, aligning with the recent price action.
* **Delta_Previous_Relative_Divergence:** -6.21 (-) – This signifies a short-term downtrend in relative divergence, meaning that the stock's price movement has weakened compared to the broader market.
* **Expected Return:** 0.0% – Based on current market conditions, the stock is expected to perform in line with the S&P 500 over the long term (2 years or more).

**4. Recent Earnings and Outlook:**

JNJ's recent earnings have been mixed, with some quarters exceeding expectations and others falling short. The latest earnings report (2024-10-23) showed EPS of $1.12, slightly exceeding analyst expectations of $1.08. 

**Earnings Table:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |

Despite the recent mixed earnings, analysts remain generally optimistic about JNJ's long-term prospects, citing its strong brand, diverse product portfolio, and continued investment in research and development.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $22.47B | 69.01% |
| 2024-06-30 | $22.45B | 69.40% |
| 2024-03-31 | $21.38B | 69.55% |
| 2023-12-31 | $21.39B | 68.23% |
| 2023-09-30 | $21.35B | 69.06% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $70.16B | 3.84% |
| 2024-06-30 | $71.54B | 6.55% |
| 2024-03-31 | $70.02B | 4.65% |
| 2023-12-31 | $68.77B | 5.89% |
| 2023-09-30 | $71.23B | 36.54% |

JNJ's financial performance demonstrates consistent profitability and strong revenue generation. The company's high profit margin and robust equity position highlight its financial strength and resilience.

**6. News and Recent Events:**

**Earnings News:**

Recent earnings reports haven't shown any significant surprise or unexpected events. Analysts have primarily focused on the company's future growth potential in emerging markets and its ongoing divestiture of its consumer health business.

**Recent Market Outlook:**

Despite the recent underperformance, many analysts remain bullish on JNJ's long-term prospects. The company's strong dividend track record, its dominance in the pharmaceutical and medical device industries, and its focus on innovation are key factors cited for their optimism.

**Analyst Opinions and Performance Highlights:**

According to FINBOLD, JNJ has an average rating of "Buy" among analysts. The consensus price target is $175.60, which represents a potential upside of approximately 14% from its current price.

**7. Overall Analysis:**

While Johnson & Johnson has underperformed the S&P 500 in the recent past, its solid financial position, diverse product portfolio, and robust dividend track record offer long-term investment appeal. The stock's recent price action indicates a short-term downtrend, but the oversold RSI suggests a potential rebound. While the current expected return is in line with the market, the company's strong fundamentals and long-term growth prospects could make it a valuable addition to a diversified portfolio for investors with a long-term horizon.

**8. Conclusion:**

JNJ's stock price has been under pressure recently, and its performance has lagged the broader market. However, the company's strong financial position, robust dividend track record, and focus on innovation make it a worthwhile investment for investors seeking long-term value. The stock's recent oversold RSI and potential for a rebound suggest that it may be an attractive buy at current levels, especially for investors with a long-term investment horizon.